Dr. Debjit Chattopadhyay is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on biotechnology, specifically on gene therapy, immune-oncology, and rare diseases. Prior to joining H.C. Wainwright, Dr. Chattopadhyay has been a Wall Street Healthcare Analyst, on the sell-side, working for Janney Montgomery Scott, Roth Capital Partners, and Boenning & Scattergood. Most recently, Dr. Chattopadhyay worked as the Managing Director and the Head of Biotechnology at Janney Montgomery Scott.
Analyst: Vernon T. Bernardino
Analyst
Vernon T. Bernardino is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on the healthcare sector. Specific therapeutic areas of interest include vascular diseases, gastrointestinal and autoimmune diseases, infectious diseases, metabolic and rare diseases. He possesses over 10 years of experience in the healthcare industry and over 12 years in sell-side and buy-side equity research. Prior to joining H.C. Wainwright, Mr. Bernardino was a healthcare equity research analyst at multiple Wall Street firms including Seaport Global Securities, B. Riley FBR, Rodman & Renshaw LLC, UBS Securities, and Nicholas Applegate Capital Management (now part of Allianz SE). For 2017, Mr. Bernardino was recognized by TipRanks as a Top 150 Wall Street analyst.
Analyst: Ed Arce
Analyst
Ed Arce is a Managing Director of Equity Research at H.C. Wainwright with expertise in both the biopharmaceutical and the specialty pharmaceutical sectors. In particular, Mr. Arce’s research covers investment opportunities among hepatology, renal, infectious disease, gastrointestinal, endocrine, metabolic and select rare disease companies Mr. Arce has been involved in institutionally-focused healthcare research since 2005. Prior to joining H.C. Wainwright, Mr. Arce was a Senior Research Analyst at ROTH Capital Partners. Mr. Arce’s previous sell-side experience includes working for MLV & Co, Wedbush Securities, UBS Securities and First Albany Capital.
H. C. Wainwright & Co.
Analyst
H.C. Wainwright & Co. is one of the country’s oldest financial institutions. H.C. Wainwright & Co. was founded in 1868 at the Union Bank Building in Boston, Massachusetts, located at the heart of the strongest financial center in post-Civil War America. H.C. Wainwright & Co., is a full-service investment bank dedicated to providing corporate fiance, strategic and licensing advisory, research, sales & trading, and related services to pubic and private companies. H.C. Wainwright & Co. has been the leader in the CMPU (confidentially marketed public offerings), RD (registered direct offering) and PIPE (private investment in public equity) transactions since 1998.
Article: Summit Therapeutics (SMMT) Receives a Buy from H.C. Wainwright
Article - MediaSummit Therapeutics (SMMT) Receives a Buy from H.C. Wainwright
Austin Angelo
AnalystRatings, 1 May 2020
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Summit Therapeutics (SMMT – Research Report) today and set a price target of $4.00. The company’s shares closed last Thursday at $3.75.
According to TipRanks.com, Arce is a 5-star analyst with an average return of 14.2% and a 41.9% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Collegium Pharmaceutical.
Comment: This company is at risk of collusion between a placement agent and naked short sellers.
Article: H.C. Wainwright Keeps Their Buy Rating on Insmed (INSM)
Article - MediaH.C. Wainwright Keeps Their Buy Rating on Insmed (INSM)
Jason Carr
AnalystRatings, 1 May 2020
H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Insmed (INSM – Research Report) today and set a price target of $52.00. The company’s shares closed last Thursday at $23.00.
According to TipRanks.com, Fein is a 5-star analyst with an average return of 7.7% and a 46.1% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Constellation Pharmaceuticals, and Proteostasis Therapeutics.
Comment: This company is at risk of collusion between a placement agent and naked short sellers.
Article: H.C. Wainwright Sticks to Their Buy Rating for Pluristem (PSTI)
Article - MediaH.C. Wainwright Sticks to Their Buy Rating for Pluristem (PSTI)
Christine Brown
SmarterAnalyst, 1 May 2020
In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Pluristem (PSTI), with a price target of $15.50. The company’s shares closed last Thursday at $9.17.
According to TipRanks.com, Ramakanth is a 1-star analyst with an average return of -0.7% and a 36.0% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals, IntelGenx Technologies, and Corvus Pharmaceuticals.
Comment: This company is at risk of collusion between a placement agent and naked short sellers.
Article: H.C. Wainwright Keeps a Buy Rating on CareDx (CDNA)
Article - MediaH.C. Wainwright Keeps a Buy Rating on CareDx (CDNA)
Christine Brown
SmarterAnalyst, 1 May 2020
In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on CareDx (CDNA), with a price target of $40.00. The company’s shares closed last Thursday at $25.38.
According to TipRanks.com, Chen is a 5-star analyst with an average return of 14.1% and a 43.3% success rate. Chen covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, HTG Molecular Diagnostics, and EyePoint Pharmaceuticals.
Comment: This company is at risk of collusion between a placement agent and naked short sellers.
Article: Co-Diagnostics Inc. [CODX] stock Reiterated by H.C. Wainwright analyst, price target now $20
Article - MediaCo-Diagnostics Inc. [CODX] stock Reiterated by H.C. Wainwright analyst, price target now $20
Brandon Evans
DBT News, 30 April 2020
Co-Diagnostics Inc. [NASDAQ: CODX] traded at a low on 04/29/20, posting a -8.57 loss after which it closed the day’ session at $12.37. The results of the trading session contributed to over 5099148 shares changing hands. Over the past one week, the price volatility of Co-Diagnostics Inc. stands at 10.98% while the volatility over the past one month is 12.61%.
The market cap for CODX stock reached $332.63 million, with 26.89 million shares outstanding and 20.80 million shares in the current float. Compared to the average trading volume of 12.82M shares, CODX reached a trading volume of 5099148 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Comment: This company is at risk of collusion between a placement agent and naked short sellers.
RELATED:
Article: H.C. Wainwright Keeps Their Hold Rating on PDS Biotechnology (PDSB)
Article - MediaH.C. Wainwright Keeps Their Hold Rating on PDS Biotechnology (PDSB)
Ryan Adist
SmarterAnalyst, 30 April 2020
H.C. Wainwright analyst Joseph Pantginis maintained a Hold rating on PDS Biotechnology (PDSB) today. The company’s shares closed last Wednesday at $0.95, close to its 52-week low of $0.62.
According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 14.5% and a 43.7% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Iovance Biotherapeutics.
Comment: This company is at risk of collusion between a placement agent and naked short sellers.
Article: Vertex Pharmaceuticals (VRTX) Receives a Buy from H.C. Wainwright
Article - MediaVertex Pharmaceuticals (VRTX) Receives a Buy from H.C. Wainwright
Austin Angelo
SmarterAnalyst, 30 April 2020
In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (), with a price target of $295.00. The company’s shares closed last Wednesday at $251.05.
According to TipRanks.com, Fein is a 5-star analyst with an average return of 8.9% and a 48.1% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Constellation Pharmaceuticals, and Proteostasis Therapeutics.
Comment: This company is at risk of collusion between a placement agent and naked short sellers.
Article: H.C. Wainwright Keeps a Buy Rating on Aravive (ARAV)
Article - MediaH.C. Wainwright Keeps a Buy Rating on Aravive (ARAV)
Austin Angelo
SmarterAnalyst, 30 April 2020
In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Aravive (ARAV), with a price target of $15.00. The company’s shares closed last Thursday at $12.95.
According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 14.5% and a 43.7% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Iovance Biotherapeutics.
Comment: This company is at risk of collusion between a placement agent and naked short sellers.
Article: H.C. Wainwright Maintains a Buy Rating on BerGenBio AS (BRRGF)
Article - MediaH.C. Wainwright Maintains a Buy Rating on BerGenBio AS (BRRGF)
Christine Brown
SmarterAnalyst, 29 April 2020
H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on BerGenBio AS (BRRGF) today and set a price target of NOK66.00. The company’s shares closed last Monday at $1.23.
According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 8.2% and a 41.6% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Iovance Biotherapeutics.
Comment: This company is at risk of collusion between a placement agent and naked short sellers.
RELATED:
Video: Ekso Bionics Killed by Naked Short Sellers – Is HCWainwright Culpable for Front-Running Their Death?
Video
How it works:
Article: H.C. Wainwright & Co. Once Again Ranked #1 by PlacementTracker
Article - MediaH.C. Wainwright & Co. Once Again Ranked #1 by PlacementTracker
BusinessWire, 6 February 2020
H.C. Wainwright & Co. announced its #1 Ranking by transaction volume during 2019 maintaining the top position for 19 consecutive quarters in PlacementTracker’s Market League Tables. As noted by PlacementTracker, H.C. Wainwright effectuated more than 3 times the number of transactions than any other firm in 2019.
In addition to being the #1 Investment Bank for Confidentially Marketed Public Offerings, Registered Direct and Private Placement transactions, H.C. Wainwright executed over 200 transactions in 2019 totaling over $7.6 Billion in transaction value. According to PlacementTracker, the H.C. Wainwright Team has been the #1 ranked Underwriter/Placement Agent by deal volume cumulatively since 1998.
Comment: This company is alleged to be one of the top front-runners helping naked short sellers destroy promising companies.
Learn more: HCWainwright @ NSS
